Adverum Biotechnologies Inc (NAS:ADVM)
$ 8.75 -0.18 (-2.02%) Market Cap: 181.62 Mil Enterprise Value: 163.87 Mil PE Ratio: 0 PB Ratio: 1.00 GF Score: 50/100

Adverum Biotechnologies Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 13, 2021 / 03:50PM GMT
Release Date Price: $113.8 (-3.31%)
Mike Connor
JP Morgan Chase & Co. - Executive Director of Healthcare Investment Banking

Good morning. My name is Mike Connor, and on behalf of the JPMorgan Health Care Investment Banking team, it's our pleasure to introduce Adverum Biotechnologies. As many of you know, Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a onetime individual injection for the treatment of patients with wet AMD and DME.

Today from the company, we are joined by Laurent Fischer, Chief Executive Officer; Leone Patterson, President; and Aaron Osborne, Chief Medical Officer.

I'll now turn it over to Laurent and the team to walk through the presentation. Laurent?

Laurent Fischer
Adverum Biotechnologies, Inc. - CEO & Director

Thank you, Mike. Good morning, everybody. I'd like to first thank JPMorgan for inviting Adverum to present today. And I hope that everybody is doing well and staying safe at home. These are my forward-looking statements on Slide 2. They are also available in our SEC filing and on the Adverum

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot